Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Carbamazepine Tablets USP ...

Shares MSCI Switzerland ETF's high allocation to Nestle, Roche, and Novartis poses diversification risks. Read why EWL is a ...

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis knee pain. | Novartis has terminated a phase 2 trial evaluating an ...

Droplet digital polymerase chain reaction (PCR) measurements of cell-free, circulating tumor DNA (ctDNA) can identify ...

New York University researchers say a simple, gene-based blood test has shown to be highly accurate in predicting whether ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, Texas, Indiana, and New Jersey.

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Healthcare stocks ended a volatile Wall Street week on a positive note. Explore top movers, Novartis' $23B U.S.

Swiss pharmaceutical giant Novartis announced it will spend $23 billion to build and expand 10 facilities in the United ...

Swiss pharmaceutical giant Novartis announced Thursday that it plans to build a $1.1 billion research hub in San Diego as ...